Access the Industry’s Most Diverse Fully-Human Antibody Discovery Platform,
Royalty-Free
The Atlas™ Full Human Diversity Mouse is available through Mosaic Biosciences under a milestone and royalty-free access model, capturing full human diversity for the heavy chain and κ light chain loci.
V-regions covering >99% of known and expressed human sequences
Variable sequences designed to avoid patented or FTO-excluded variants
Validated across multiple immunogens
FHD Mice Generate More Sequence Diversity at Comparable Titers
In a head-to-head CD22 campaign comparing Atlas FHD mice against wild-type (WT) mice, serum titers were comparable across both groups, meaning immunization conditions were equivalent. Despite identical effort, FHD mice generated significantly more IgG-producing B cells, more antigen-positive B cells, and more unique antibodies than WT mice. Of the unique CD22-positive hits recovered, 84% came from Atlas FHD mice versus 63% from WT.
More sequence diversity from the same campaign means more candidate options, without additional cost or time. Following immunization, 42 of 42 heavy chain V-genes were observed in use, not just present in the transgene, but actively expressed. Real breadth, not catalog insertion.
8 competition bins were identified across 17 candidate antibodies.
8 Distinct Epitope Bins Across 17 Candidate Antibodies
Epitope diversity isn’t just a discovery metric, it’s a drug development asset. Broader epitope coverage gives programs more mechanistic options and more flexibility as development advances. Using SPR-based epitope binning across all candidate antibodies recovered from the CD22 campaign, 8 distinct competition bins were identified across 17 candidates. FHD mouse sequences were represented in all 8 bins.
Strong Affinity Range With Favorable Developability Profiles
A broader sequence pool is only valuable if the resulting candidates are drug-like. Across the FHD candidate antibody set, developability profiling showed strong results across all five assessed parameters: hydrophobicity (HIC-HPLC), self-interaction (AC-SINS), polyreactivity (BVP ELISA), and thermal stability (Tm and Tagg). The majority of candidates earned green-flag scores, with very few red-flag results across any single assay.
“Variable sequences used avoid patented or FTO-excluded variants.”
Designed for Freedom to Operate From Day One
IP risk is one of the most costly surprises in antibody drug development — and one of the most preventable. The Atlas™ Full Human Diversity Mouse was specifically designed so that the variable sequences used avoid patented or FTO-excluded variants. The V-regions comprising the Atlas™ platform cover more than 99% of known and expressed human sequences, selected to give programs the broadest possible sequence space without the IP entanglements that can derail development downstream.
Access is structured as a milestone and royalty-free model, meaning your program’s commercial trajectory isn’t encumbered from the start.
Ready to Advance Your Lead Candidate?
Tell us about your molecule and your goals.
Experts From the World’s Top Organizations
Eric Furfine, PhD
Chief Scientific Officer
Led IPO-financed Phase 3 programs at Eleven Biotherapeutics. Built the Adnectin platform (acquired by BMS). Former VP at Regeneron contributing to Eylea development.
Tracy Mullen
Chief Strategy Officer
Former SVP Biopharma at Twist Bioscience (post-Abveris acquisition). Former CEO of Abveris. Antibody discovery leadership experience at Biogen and Adimab platform implementation.
Alexei Kazantsev, PhD
VP Protein Design and Engineering
Structural and chemical biology expert. Leads protein engineering and PK optimization at Mosaic. Prior research in RNA and protein structural biology using X-ray crystallography and SAXS.
Scott Glaser PhD
SVP, Biologics Discovery
30+ years in biologic drug discovery. Former Director of Antibody Therapeutics at Novartis (GNF) and senior leadership at Pfizer and Biogen. Contributor to 50+ discovery programs and co-inventor on 23 US patents.
Start a conversation with our scientific team about your discovery program today
216+
Discovery programs completed to date.
80%
Of scientific staff hold advanced degrees (PhD/MS).
504+
Peer-reviewed publications and patents authored by Mosaic scientists.
50+
Experienced scientists and program leaders.
100%
Research conducted in the USA.